<DOC>
	<DOCNO>NCT02797522</DOCNO>
	<brief_summary>Normal healthy volunteer ( NHVs ) enroll sequentially total 6 escalate dose level randomize receive ARC-521 Injection placebo . Hepatitis B e Antigen ( HBeAg ) negative Chronic Hepatitis B patient ( CHBs ) enroll sequentially total 3 dose level receive open-label ARC-521 Injection .</brief_summary>
	<brief_title>A Study ARC-521 Injection Normal Adult Volunteers Patients With Chronic Hepatitis B</brief_title>
	<detailed_description>Phase 1a/1b multicenter dose-escalation study ARC-521 Injection normal healthy volunteer patient chronic hepatitis B . Eligible participant sign Ethics Committee ( EC ) /Institutional Review Board ( IRB ) approve informed consent form meet protocol eligibility criterion enrol follow : - Normal healthy volunteer enroll sequentially total 6 escalate dose level ( 6 subject per dose level ) , randomize receive single dose ARC-521 Injection placebo . The maximum study duration NHVs approximately 21 week . - HBeAg negative CHB patient enroll sequentially 3 dose level ( 8 patient per dose level ) receive multiple dos open label ARC-521 Injection . For CHB patient maximum study duration approximately 37 week . Patients undergo following evaluation regular interval study : medical history , physical examination , vital sign measurement ( blood pressure , heart rate , respiratory rate , temperature ) , weight , adverse event assessment ( AEs ) , concomitant medications/therapies assessment , electrocardiogram ( ECGs ) , telemetry [ NHVs ] , measure hepatic fibrosis [ CHBs ] , blood sample collection hematology , coagulation , chemistry , Pharmacokinetics ( PK ) [ NHVs ] , metabolic analysis [ NHVs ] , exploratory Pharmacodynamic ( PD ) measure , urinalysis , HBV serology , immunogenicity , Follicle Stimulating Hormone ( FSH ) test ( post-menopausal female ) pregnancy test female childbearing potential . Clinically significant change include AEs follow resolution , condition stabilizes , event otherwise explain , patient lose follow-up . Prior enrollment 60 day screen period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Male female , 18 55 year age inclusive [ NHVs ] 1865 year age inclusive [ CHBs ] , time informed consent Able provide write informed consent prior performance study specific procedure Body mass index ( BMI ) 19.0 35.0 kg/m2 , inclusive A 12lead ECG Screening predose assessment , opinion investigator , abnormality compromise participant 's safety study Must use 2 effective method contraception ( double barrier contraception hormonal contraceptive along barrier contraceptive ( male female partner ) Have suitable venous access blood sample No abnormal find clinical relevance Screening evaluation [ NHVs ] Have diagnosis HbeAg negative Chronic HBV infection [ CHB patient ] Treatment naive currently entecavir/tenofovir 6 month longer Pregnant lactate Acute sign hepatitis/other infection Screening baseline Use within last 14 day anticipate requirement anticoagulant , systemic corticosteroid , immunomodulators , immunosuppressant Use prescription medication within 14 day prior study treatment opinion PI Sponsor would interfere study conduct . Known diagnosis nonalcoholic steatohepatitis [ NHVs ] familial hypercholesterolemia Taking interferon alpha ( INFalpha ) within 6 month screen [ CHBs ] History poorly control autoimmune disease history autoimmune hepatitis Human immunodeficiency virus ( HIV ) infection Seropositive Hepatitis B Virus ( HBV ) [ NHVs ] Hepatitis C Virus ( HCV ) , and/or history delta virus hepatitis Hypertension define blood pressure &gt; 170/100 mmHg screen [ NHVs ] A history cardiac rhythm disturbance Family history congenital long QT syndrome , Brugada syndrome unexplained sudden cardiac death Symptomatic heart failure , unstable angina , myocardial infarction , severe cardiovascular disease within 6 month prior study entry History malignancy within last 5 year except adequately treat basal cell carcinoma , squamous cell skin cancer , superficial bladder tumor , situ cervical cancer History major surgery within 3 month Screening Regular use alcohol within one month prior Screening visit ( fourteen unit alcohol per week ) Evidence severe systemic acute inflammation , sepsis , hemolysis [ NHVs ] Use within 3 month illicit drug ( cocaine , phencyclidine [ PCP ] , 3,4methylenedioxymethamphetamine [ MDMA ] , others ) positive test drug abuse screen . History allergy bee venom history severe hypersensitivity reaction , anaphylaxis Use investigational agent device within 30 day prior dose current participation investigational study Clinically significant history alcoholic liver disease , cirrhosis , Wilson 's disease , hemochromatosis , alpha1 antitrypsin deficiency , liver kidney disease Clinically significant history/presence poorly control decompensated neurological , endocrine , cardiovascular , pulmonary , hematological , immunologic , psychiatric , metabolic , uncontrolled systemic disease Blood donation ( 500 mL ) within 7 day prior study treatment administration [ NHVs ] History fever ( &gt; 38.0ºC/100.4ºF ) within 2 week Screening [ NHVs ] Any concomitant medical psychiatric condition social situation impact compliance involve additional safety risk History coagulopathy ( include deep vein thrombosis pulmonary embolism ) stroke within 6 month baseline , and/or concurrent anticoagulant medication ( ) Presence cholangitis , cholecystitis , cholestasis , duct obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>